Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!
Fresenius Kabi Introduces Bivalirudin...
Home  »  Community News  »  Fresenius Kabi Intro...
Sandeep Singh Dhillon
Fresenius Kabi Introduces Bivalirudin for Injection
Pharma News

Fresenius Kabi announced today it has introduced Bivalirudin for Injection in the United States. Bivalirudin for Injection, an anticoagulant, is a generic alternative to Angiomax®. Fresenius Kabi Bivalirudin was approved by the U.S. Food and Drug Administration in October. According to IMS the U.S. market for Bivalirudin for Injection is approximately $240 million.

Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition.

Fresenius Kabi Bivalirudin for Injection is available in single-dose vials, each containing 250 mg of Bivalirudin. The drug was developed and is manufactured in the United States.

“We are pleased to offer a generic alternative to Angiomax,” said John Ducker, president and CEO of Fresenius Kabi USA. “This addition to our portfolio of critical care medicines is the most recent example of the commitment Fresenius Kabi makes to putting essential medicines in the hands of people who care for patients.”

Bivalirudin for Injection is a direct thrombin inhibitor indicated for use as an anticoagulant in patients:

  • with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
  • undergoing percutaneous coronary intervention (PCI) with provisional use of glycoprotein IIb/IIIa inhibitor (GPI) as in the REPLACE-2 study.
  • with, or at risk of, heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia and thrombosis syndrome (HITTS), undergoing PCI. Bivalirudin for Injection is intended for use with aspirin.

Leave a reply

You must be logged in to post a comment.